{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T11:35:48Z","timestamp":1794483348203,"version":"4.9.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Karolinska University Hospital","award":["MDK 929958"],"award-info":[{"award-number":["MDK 929958"]}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["CAN 2020\/46"],"award-info":[{"award-number":["CAN 2020\/46"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007232","name":"Radiumhemmets Forskningsfonder","doi-asserted-by":"publisher","award":["224053"],"award-info":[{"award-number":["224053"]}],"id":[{"id":"10.13039\/501100007232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocr Pathol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Papillary thyroid carcinoma (PTC) is the most common form of well-differentiated thyroid cancer (WDTC) and generally has a favorable prognosis. However, subsets of these tumors can metastasize, leading to aggressive disease progression and poorer clinical outcomes. Radioactive iodine (RAI) therapy is routinely given in the adjuvant setting following thyroidectomy and lymph node dissection for WDTC. Nevertheless, its therapeutic efficacy is limited to tumors with high iodine avidity. Early post-surgical classification of thyroid cancers as either iodine-avid or refractory is crucial for enabling more personalized and effective treatment strategies. In this study, we aimed to identify transcriptomic determinants associated with RAI refractoriness (RAI-R) to improve prognostication. We collected clinicopathologic data and conducted RNA-seq on 36 tissue samples (18 high-avidity and 18 low-avidity), each uniquely characterized by ex vivo iodine concentration measurements taken directly from surgical specimens. Whole-transcriptomic analysis identified 63 differentially expressed genes, with six (\n                    <jats:italic>S100A4<\/jats:italic>\n                    ,\n                    <jats:italic>CRTC2<\/jats:italic>\n                    ,\n                    <jats:italic>ANO1<\/jats:italic>\n                    ,\n                    <jats:italic>WWTR1<\/jats:italic>\n                    ,\n                    <jats:italic>DEPTOR<\/jats:italic>\n                    ,\n                    <jats:italic>MT1G<\/jats:italic>\n                    ) showing consistent deregulation. The expression of ANO1, an established iodine transporter at the apical membrane of the thyroid follicular cells, correlated significantly with iodine avidity (\n                    <jats:italic>r<\/jats:italic>\n                    \u2009=\u20090.54). Validation via RT-qPCR confirmed differential expression trends. Gene ontology and pathway enrichment analyses highlighted thyroid hormone synthesis, PI3K-AKT, and MAPK signaling pathways as key regulators of RAI avidity. A refined multivariate predictive model incorporating\n                    <jats:italic>ANO1<\/jats:italic>\n                    mRNA expression, histological subtypes, and sample type demonstrated strong predictive performance (adjusted\n                    <jats:italic>R<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    \u2009=\u20090.55). These findings suggest\n                    <jats:italic>ANO1<\/jats:italic>\n                    as a promising biomarker for predicting iodine avidity in thyroid cancer.\n                  <\/jats:p>","DOI":"10.1007\/s12022-025-09849-0","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:16:21Z","timestamp":1740096981000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Comprehensive Gene Expression Analysis in Papillary Thyroid Carcinoma Reveals a Transcriptional Profile Associated with Reduced Radioiodine Avidity"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4569-5398","authenticated-orcid":false,"given":"Vincenzo","family":"Condello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Marchettini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina","family":"Ihre-Lundgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7496-9189","authenticated-orcid":false,"given":"Joachim N.","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5945-9081","authenticated-orcid":false,"given":"C. Christofer","family":"Juhlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"9849_CR1","first-page":"3","volume":"35","author":"L Agate","year":"2012","unstructured":"Agate L, Lorusso L, Elisei R (2012) New and old knowledge on differentiated thyroid cancer epidemiology and risk factors. J Endocrinol Invest 35:3\u20139","journal-title":"J Endocrinol Invest"},{"key":"9849_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","volume":"33","author":"ZW Baloch","year":"2022","unstructured":"Baloch ZW, Asa SL, Barletta JA, et al (2022) Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocr Pathol 33:27\u201363. https:\/\/doi.org\/10.1007\/s12022-022-09707-3","journal-title":"Endocr Pathol"},{"key":"9849_CR3","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-21-0046","volume":"11","author":"F Pacini","year":"2022","unstructured":"Pacini F, Fuhrer D, Elisei R, et al (2022) 2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer? Eur Thyroid J 11:e210046. https:\/\/doi.org\/10.1530\/ETJ-21-0046","journal-title":"Eur Thyroid J"},{"key":"9849_CR4","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.3390\/curroncol31070286","volume":"31","author":"F Volpe","year":"2024","unstructured":"Volpe F, Nappi C, Zampella E, et al (2024) Current Advances in Radioactive Iodine-Refractory Differentiated Thyroid Cancer. Current Oncology 31:3870\u20133884. https:\/\/doi.org\/10.3390\/curroncol31070286","journal-title":"Current Oncology"},{"key":"9849_CR5","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1210\/jc.2005-2838","volume":"91","author":"C Durante","year":"2006","unstructured":"Durante C, Haddy N, Baudin E, et al (2006) Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91:2892\u20132899. https:\/\/doi.org\/10.1210\/jc.2005-2838","journal-title":"J Clin Endocrinol Metab"},{"key":"9849_CR6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12022-024-09836-x","volume":"35","author":"O Mete","year":"2024","unstructured":"Mete O, Boucher A, Schrader KA, et al (2024) Consensus Statement: Recommendations on Actionable Biomarker Testing for Thyroid Cancer Management. Endocr Pathol 35:293\u2013308. https:\/\/doi.org\/10.1007\/s12022-024-09836-x","journal-title":"Endocr Pathol"},{"key":"9849_CR7","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1097\/RLU.0000000000002078","volume":"43","author":"K Nakanishi","year":"2018","unstructured":"Nakanishi K, Kikumori T, Miyajima N, et al (2018) Impact of Patient Age and Histological Type on Radioactive Iodine Avidity of Recurrent Lesions of Differentiated Thyroid Carcinoma. Clin Nucl Med 43:482\u2013485. https:\/\/doi.org\/10.1097\/RLU.0000000000002078","journal-title":"Clin Nucl Med"},{"key":"9849_CR8","doi-asserted-by":"publisher","first-page":"E829","DOI":"10.1210\/jc.2012-3933","volume":"98","author":"MM Sabra","year":"2013","unstructured":"Sabra MM, Dominguez JM, Grewal RK, et al (2013) Clinical Outcomes and Molecular Profile of Differentiated Thyroid Cancers With Radioiodine-Avid Distant Metastases. The Journal of Clinical Endocrinology & Metabolism 98:E829\u2013E836. https:\/\/doi.org\/10.1210\/jc.2012-3933","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"key":"9849_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2967\/jnumed.119.227652","volume":"61","author":"J Liu","year":"2020","unstructured":"Liu J, Liu R, Shen X, et al (2020) The Genetic Duet of BRAF V600E and TERT Promoter Mutations Robustly Predicts Loss of Radioiodine Avidity in Recurrent Papillary Thyroid Cancer. J Nucl Med 61:177\u2013182. https:\/\/doi.org\/10.2967\/jnumed.119.227652","journal-title":"J Nucl Med"},{"key":"9849_CR10","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3389\/fendo.2020.00485","volume":"11","author":"BA McKelvey","year":"2020","unstructured":"McKelvey BA, Umbricht CB, Zeiger MA (2020) Telomerase Reverse Transcriptase (TERT) Regulation in Thyroid Cancer: A Review. Front Endocrinol 11:485. https:\/\/doi.org\/10.3389\/fendo.2020.00485","journal-title":"Front Endocrinol"},{"key":"9849_CR11","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1146\/annurev-physiol-022516-034125","volume":"79","author":"S Ravera","year":"2017","unstructured":"Ravera S, Reyna-Neyra A, Ferrandino G, et al (2017) The Sodium\/Iodide Symporter (NIS): Molecular Physiology and Preclinical and Clinical Applications. Annu Rev Physiol 79:261\u2013289. https:\/\/doi.org\/10.1146\/annurev-physiol-022516-034125","journal-title":"Annu Rev Physiol"},{"key":"9849_CR12","doi-asserted-by":"publisher","first-page":"1437360","DOI":"10.3389\/fonc.2024.1437360","volume":"14","author":"S Ezzat","year":"2024","unstructured":"Ezzat S, Pasternak JD, Rajaraman M, et al (2024) Multidisciplinary Canadian consensus on the multimodal management of high-risk and radioactive iodine-refractory thyroid carcinoma. Front Oncol 14:1437360. https:\/\/doi.org\/10.3389\/fonc.2024.1437360","journal-title":"Front Oncol"},{"key":"9849_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1089\/10507250150500649","volume":"11","author":"D Russo","year":"2001","unstructured":"Russo D, Manole D, Arturi F, et al (2001) Absence of Sodium\/Iodide Symporter Gene Mutations in Differentiated Human Thyroid Carcinomas. Thyroid 11:37\u201339. https:\/\/doi.org\/10.1089\/10507250150500649","journal-title":"Thyroid"},{"key":"9849_CR14","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/ncpendmet0449","volume":"3","author":"M Schlumberger","year":"2007","unstructured":"Schlumberger M, Lacroix L, Russo D, et al (2007) Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nat Rev Endocrinol 3:260\u2013269. https:\/\/doi.org\/10.1038\/ncpendmet0449","journal-title":"Nat Rev Endocrinol"},{"key":"9849_CR15","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/nrendo.2011.142","volume":"7","author":"YE Nikiforov","year":"2011","unstructured":"Nikiforov YE, Nikiforova MN (2011) Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 7:569\u2013580. https:\/\/doi.org\/10.1038\/nrendo.2011.142","journal-title":"Nat Rev Endocrinol"},{"key":"9849_CR16","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.1172\/JCI46382","volume":"121","author":"D Chakravarty","year":"2011","unstructured":"Chakravarty D, Santos E, Ryder M, et al (2011) Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest 121:4700\u20134711. https:\/\/doi.org\/10.1172\/JCI46382","journal-title":"J Clin Invest"},{"key":"9849_CR17","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1056\/NEJMoa1209288","volume":"368","author":"AL Ho","year":"2013","unstructured":"Ho AL, Grewal RK, Leboeuf R, et al (2013) Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer. N Engl J Med 368:623\u2013632. https:\/\/doi.org\/10.1056\/NEJMoa1209288","journal-title":"N Engl J Med"},{"key":"9849_CR18","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1056\/NEJMc2023094","volume":"383","author":"L Groussin","year":"2020","unstructured":"Groussin L, Clerc J, Huillard O (2020) Larotrectinib-Enhanced Radioactive Iodine Uptake in Advanced Thyroid Cancer. N Engl J Med 383:1686\u20131687. https:\/\/doi.org\/10.1056\/NEJMc2023094","journal-title":"N Engl J Med"},{"key":"9849_CR19","doi-asserted-by":"publisher","first-page":"e144847","DOI":"10.1172\/JCI144847","volume":"131","author":"YA Lee","year":"2021","unstructured":"Lee YA, Lee H, Im S-W, et al (2021) NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake. J Clin Invest 131:e144847. https:\/\/doi.org\/10.1172\/JCI144847","journal-title":"J Clin Invest"},{"key":"9849_CR20","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1089\/thy.2022.0533","volume":"33","author":"AV Nikitski","year":"2023","unstructured":"Nikitski AV, Condello V, Divakaran SS, Nikiforov YE (2023) Inhibition of ALK-Signaling Overcomes STRN-ALK-Induced Downregulation of the Sodium Iodine Symporter and Restores Radioiodine Uptake in Thyroid Cells. Thyroid 33:464\u2013473. https:\/\/doi.org\/10.1089\/thy.2022.0533","journal-title":"Thyroid"},{"key":"9849_CR21","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1158\/1078-0432.CCR-22-2882","volume":"29","author":"L Boucai","year":"2023","unstructured":"Boucai L, Saqcena M, Kuo F, et al (2023) Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy. Clin Cancer Res 29:1620\u20131630. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2882","journal-title":"Clin Cancer Res"},{"key":"9849_CR22","doi-asserted-by":"publisher","first-page":"101013","DOI":"10.1016\/j.drup.2023.101013","volume":"72","author":"H Shen","year":"2024","unstructured":"Shen H, Zhu R, Liu Y, et al (2024) Radioiodine-refractory differentiated\u00a0thyroid cancer: Molecular mechanisms and therapeutic strategies for radioiodine resistance. Drug Resist Updat 72:101013. https:\/\/doi.org\/10.1016\/j.drup.2023.101013","journal-title":"Drug Resist Updat"},{"key":"9849_CR23","doi-asserted-by":"publisher","first-page":"e230099","DOI":"10.1530\/ETJ-23-0099","volume":"12","author":"JN Nilsson","year":"2023","unstructured":"Nilsson JN, Siikanen J, Condello V, et al (2023) Iodine avidity in papillary and poorly differentiated thyroid cancer is predicted by immunohistochemical and molecular work-up. Eur Thyroid J 12:e230099. https:\/\/doi.org\/10.1530\/ETJ-23-0099","journal-title":"Eur Thyroid J"},{"key":"9849_CR24","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.3390\/cancers13143627","volume":"13","author":"JN Nilsson","year":"2021","unstructured":"Nilsson JN, Siikanen J, Hedman C, et al (2021) Pre-Therapeutic Measurements of Iodine Avidity in Papillary and Poorly Differentiated Thyroid Cancer Reveal Associations with Thyroglobulin Expression, Histological Variants and Ki-67 Index. Cancers (Basel) 13:3627. https:\/\/doi.org\/10.3390\/cancers13143627","journal-title":"Cancers (Basel)"},{"key":"9849_CR25","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.2967\/jnumed.108.061150","volume":"50","author":"C Lundh","year":"2009","unstructured":"Lundh C, Lindencrona U, Postg\u00e5rd P, et al (2009) Radiation-induced thyroid stunning: differential effects of (123)I, (131)I, (99m)Tc, and (211)At on iodide transport and NIS mRNA expression in cultured thyroid cells. J Nucl Med 50:1161\u20131167. https:\/\/doi.org\/10.2967\/jnumed.108.061150","journal-title":"J Nucl Med"},{"key":"9849_CR26","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s12020-023-03414-7","volume":"82","author":"JN Nilsson","year":"2023","unstructured":"Nilsson JN, Gryb\u00e4ck P, Juhlin CC, et al (2023) Primary tumour iodine avidity in relation to uptake in persistent metastatic disease in papillary and poorly differentiated thyroid cancer. Endocrine 82:343\u2013352. https:\/\/doi.org\/10.1007\/s12020-023-03414-7","journal-title":"Endocrine"},{"key":"9849_CR27","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1210\/clinem\/dgab471","volume":"106","author":"JO Paulsson","year":"2021","unstructured":"Paulsson JO, Rafati N, DiLorenzo S, et al (2021) Whole-genome Sequencing of Follicular Thyroid Carcinomas Reveal Recurrent Mutations in MicroRNA Processing Subunit DGCR8. J Clin Endocrinol Metab 106:3265\u20133282. https:\/\/doi.org\/10.1210\/clinem\/dgab471","journal-title":"J Clin Endocrinol Metab"},{"key":"9849_CR28","doi-asserted-by":"publisher","first-page":"5121","DOI":"10.1038\/s41388-022-02499-0","volume":"41","author":"S Hong","year":"2022","unstructured":"Hong S, Xie Y, Cheng Z, et al (2022) Distinct molecular subtypes of papillary thyroid carcinoma and gene signature with diagnostic capability. Oncogene 41:5121\u20135132. https:\/\/doi.org\/10.1038\/s41388-022-02499-0","journal-title":"Oncogene"},{"key":"9849_CR29","doi-asserted-by":"crossref","first-page":"6461","DOI":"10.1109\/EMBC.2015.7319872","volume-title":"2015 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC)","author":"Ying Sha","year":"2015","unstructured":"Ying Sha, Phan JH, Wang MD (2015) Effect of low-expression gene filtering on detection of differentially expressed genes in RNA-seq data. In: 2015 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC). IEEE, Milan, pp 6461\u20136464"},{"key":"9849_CR30","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15:550. https:\/\/doi.org\/10.1186\/s13059-014-0550-8","journal-title":"Genome Biol"},{"key":"9849_CR31","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/MED.0000000000000188","volume":"22","author":"JC Silveira","year":"2015","unstructured":"Silveira JC, Kopp PA (2015) Pendrin and anoctamin as mediators of apical iodide efflux in thyroid cells. Curr Opin Endocrinol Diabetes Obes 22:374\u2013380. https:\/\/doi.org\/10.1097\/MED.0000000000000188","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"9849_CR32","doi-asserted-by":"publisher","first-page":"153663","DOI":"10.1016\/j.prp.2021.153663","volume":"228","author":"K Jansen","year":"2021","unstructured":"Jansen K, Farahi N, B\u00fcscheck F, et al (2021) DOG1 expression is common in human tumors: A tissue microarray study on more than 15,000 tissue samples. Pathol Res Pract 228:153663. https:\/\/doi.org\/10.1016\/j.prp.2021.153663","journal-title":"Pathol Res Pract"},{"key":"9849_CR33","doi-asserted-by":"publisher","first-page":"C1102","DOI":"10.1152\/ajpcell.00126.2014","volume":"307","author":"L Twyffels","year":"2014","unstructured":"Twyffels L, Strickaert A, Virreira M, et al (2014) Anoctamin-1\/TMEM16A is the major apical iodide channel of the thyrocyte. Am J Physiol Cell Physiol 307:C1102-1112. https:\/\/doi.org\/10.1152\/ajpcell.00126.2014","journal-title":"Am J Physiol Cell Physiol"},{"key":"9849_CR34","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1159\/000366313","volume":"34","author":"C Iosco","year":"2014","unstructured":"Iosco C, Cosentino C, Sirna L, et al (2014) Anoctamin 1 is apically expressed on thyroid follicular cells and contributes to ATP- and calcium-activated iodide efflux. Cell Physiol Biochem 34:966\u2013980. https:\/\/doi.org\/10.1159\/000366313","journal-title":"Cell Physiol Biochem"},{"key":"9849_CR35","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s12022-023-09769-x","volume":"34","author":"J Metovic","year":"2023","unstructured":"Metovic J, Cabutti F, Osella-Abate S, et al (2023) Clinical and Pathological Features and Gene Expression Profiles of Clinically Aggressive Papillary Thyroid Carcinomas. Endocr Pathol 34:298\u2013310. https:\/\/doi.org\/10.1007\/s12022-023-09769-x","journal-title":"Endocr Pathol"}],"container-title":["Endocrine Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-025-09849-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12022-025-09849-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-025-09849-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:25:39Z","timestamp":1767860739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12022-025-09849-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["9849"],"URL":"https:\/\/doi.org\/10.1007\/s12022-025-09849-0","relation":{},"ISSN":["1046-3976","1559-0097"],"issn-type":[{"value":"1046-3976","type":"print"},{"value":"1559-0097","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"11 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Swedish Ethical Review Authority (#2020\u201301222, #2020\u201301541 and #2015_959-31).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"4"}}